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Spinal muscular atrophy is a motor neuron disorder caused by mutations in SMN1. The reasons for the selective vulnerability of 
motor neurons linked to SMN (encoded by SMN1) reduction remain unclear. Therefore, we performed deep RNA sequencing on 
human spinal muscular atrophy motor neurons to detect speciﬁc altered gene splicing/expression and to identify the presence of a 
common sequence motif in these genes. Many deregulated genes, such as the neurexin and synaptotagmin families, are implicated 
in critical motor neuron functions. Motif-enrichment analyses of differentially expressed/spliced genes, including neurexin2 
(NRXN2), revealed a common motif, motif 7, which is a target of SYNCRIP. Interestingly, SYNCRIP interacts only with full- 
length SMN, binding and modulating several motor neuron transcripts, including SMN itself. SYNCRIP overexpression rescued 
spinal muscular atrophy motor neurons, due to the subsequent increase in SMN and their downstream target NRXN2 through a 
positive loop mechanism and ameliorated SMN-loss-related pathological phenotypes in Caenorhabditis elegans and mouse models. 
SMN/SYNCRIP complex through motif 7 may account for selective motor neuron degeneration and represent a potential thera- 
peutic target. 
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Introduction 
Spinal muscular atrophy (SMA) is a severe genetic neuro- 
muscular disease with early onset and represents the most 
common genetic cause of infant mortality (Pellizzoni et al., 
1998; Faravelli et al., 2015). Affected children present atro- 
phic muscular masses, weak and hypotonic limbs, and life- 
threatening   respiratory   complications   (Pellizzoni   et  al., 
1998; Faravelli et al., 2015). SMA is caused by mutations 
in the survival motor neuron 1 gene (SMN1), which im- 
pairs the function and survival of lower motor neurons in   
the spinal cord (Lefebvre et al., 1995), but why deﬁciency 
in this ubiquitously expressed protein primarily affects 
motor neurons is unclear. 
The majority of current SMA therapeutic approaches, 
such as nusinersen, the only compound recently approved 
by the FDA/EMA (www.curesma.it), are focused on 
increasing the levels of full-length SMN protein (Pellizzoni 
et al., 1998; Foust et al., 2010; Faravelli et al., 2015). 
However, SMN-independent approaches to target down- 
stream pathological events can be valuable as complemen- 
tary strategies, particularly in the symptomatic phase of the 
disease. Furthermore, understanding the complex series of 
mechanisms and pathways responsible for the effect of  
SMN deﬁciency is crucial for monitoring therapeutic efﬁ- 
cacy and allowing further therapeutic progress,  including 
the development of novel effective cures. 
SMN plays a key role in RNA splicing (Pellizzoni et al., 
1998), but its precise function is not completely clear. The 
absence of SMN causes improper assembly of spliceosomal 
small nuclear ribonucleoproteins (snRNPs), leading to im- 
paired splicing. SMN may also play a direct role in splicing, 
interacting transiently with components of the splicing ma- 
chinery, acting prior to their assembly into the spliceosome 
(Mourelatos et al., 2001), suggesting a direct molecular link 
between SMN, pre-mRNA splicing, and other RNA pro- 
cessing events that could be impaired when levels of full- 
length SMN are reduced. 
Many studies have documented the association between 
SMN and several RNA binding proteins  (RBPs)  that  are 
not part of the SMN complex, such as HuD or heteroge- 
neous nuclear ribonucleoprotein (hnRNP) R, fragile X 
mental retardation protein (FMRP), and amyotrophic  lat- 
eral sclerosis-related proteins FUS and TDP43. These fac- 
tors are involved in the splicing, transport, stability, and 
translation of mRNAs, among other aspects of RNA me- 
tabolism (Pellizzoni et al., 1998). 
Alterations  in  gene  expression  and  splicing   have  been 
shown in tissues derived from SMA mice (Zhang et al., 
2008, 2013; Lotti et al., 2012; Maeda et al., 2014) and 
patient samples (Corti et al., 2012; Ng et al., 2015). 
However, analyses of the correlation between SMN defects, 
speciﬁc gene expression, and splicing alterations in human 
SMA  motor  neurons,  and   studies  of   common  motif  se- 
quences present in these altered genes are  still  lacking. 
This   study   could   suggest   a   mechanistic   link  between 
aberrant transcripts and the motor neuron selective dys- 
function observed in SMA. 
To investigate these aspects, we performed RNA sequen- 
cing (RNA-Seq) of SMA motor neurons derived from pa- 
tients’ induced pluripotent stem cells (iPSCs) and healthy 
lines and we identiﬁed SMA-speciﬁc molecular changes, 
including gene expression and splicing alterations in tran- 
scripts related to cytoskeletal, axonal, and synaptic func- 
tions, such as neurexin 2 (NRXN2), a neuron-speciﬁc gene 
encoding a presynaptic cell adhesion protein involved in 
motor neuron survival and function. Other groups have 
already observed reduced expression and altered alternative 
splicing of NRXN2 in transgenic SMA mice (See et al., 
2014). In the present study,  the  overexpression  of  
NRXN2 was shown to improve  human  SMA  motor 
neuron survival and increase motor axon length, suggesting 
a role as a modiﬁer gene. 
Motif enrichment analysis of differentially expressed/ 
spliced genes in SMA motor neurons identiﬁed motif 7 as 
one of the most signiﬁcantly enriched. Notably  NRXN2 
also possesses motif 7, which is a common target sequence 
for RBPs, particularly hnRNPs. Among these, hnRNPQ 
(SYNCRIP), which is highly homologous to hnRNPR, rec- 
ognizes a large number of key motor neuron genes and is 
likely implicated in misregulation of their gene expression/ 
splicing (Mourelatos et al., 2001; Rossoll et al., 2002). This 
observation goes along with the ﬁnding that SYNCRIP pro- 
tein directly interacts only with full-length SMN and not 
with the non-functional �7 truncated form, the most 
prevalent SMN mutant found  in  SMA  patients 
(Mourelatos et al., 2001; Rossoll et  al.,  2002).  
Importantly, SYNCRIP has been studied as a splicing 
modulator of SMN, promoting the inclusion of exon 7 in 
SMN2,  probably  by  activating  the  upstream  30  splice  site 
(Chen et al., 2008). Overall, this suggests that the disrup- 
tion  of  SMN-SYNCRIP-dependent  RNA  pathways causes 
speciﬁc downstream molecular defects, including deregula- 
tion of NRXN2, which can contribute to motor  neuron  
death and axonal impairment. Interestingly, the overexpres- 
sion of SYNCRIP rescued the phenotype in our SMA cells 
due to the subsequent increase in SMN and NRXN2, 
demonstrating the presence of a positive loop among 
SYNCRIP, SMN, and NRXN2. Noteworthy, the overex- 
pression of SYNCRIP also rescued the neurodegenerative 
phenotype   observed   in   vivo   in   a   C.   elegans   model 
(Gallotta et al., 2016). This study produced novel insights 
into the role of SMN loss in mRNA processing and its 
selective effects on human SMA-motor neurons, highlight- 
ing novel targets for therapeutic strategies. 
 
 
Materials and methods 
Induced pluripotent stem cell lines 
The studies involving human samples were conducted in com- 
pliance with the Code of Ethics of the World Medical 
 
 
 
Association (Declaration of Helsinki) and with national legis- 
lation and institutional guidelines. After obtaining informed 
consent, ﬁbroblasts were generated from dermal biopsies 
(Eurobiobank) as described previously (ethical committee ap- 
proval at the IRCCS Foundation Ca’ Granda Ospedale 
Maggiore Policlinico) (Corti et al., 2012; Rizzo et al., 2016, 
2017). The iPSCs were generated by non-viral transduction  
with six reprogramming factors: OCT4, SOX2, NANOG, 
LIN28,  c-Myc,  and  KLF4  (Supplementary  Table  1;  Corti   
et al., 2012). IPSC colonies with embryonic stem cell-like 
morphology were expanded and detached for analysis. IPSCs 
were grown on Matrigel® (BD Biosciences) with E8  media 
(Life Technologies). All cell  cultures  were  maintained  at  
37oC in 5% CO2. 
 
Differentiation of iPSCs into motor 
neurons 
We generated spinal motor neurons using a multistage differ- 
entiation protocol (Corti et al., 2012; Rizzo  et  al.,  2016,  
2017). Wild-type and SMA iPSCs were plated with neuronal 
medium (DMEM/F12; Gibco, Invitrogen) supplemented with 
MEM non-essential amino acids, N2, and heparin (2 mg/ml, 
Sigma-Aldrich). After  10  days,  we  added  retinoic   acid   
(0.1 mM, Sigma-Aldrich) for neural  caudalization.  On  Day 
17, we collected the posteriorized  neuroectodermal  cells. 
These clusters were suspended for 1 week in  the  same  
medium with retinoic acid (0.1 mM) and sonic hedgehog 
(SHH; 100–200 ng/ml, R&D Systems, Inc.). On Day 24, we 
supplemented the medium with other growth factors e.g. brain-
derived neurotrophic factor (BDNF), glial-derived neuro- 
trophic factor (GDNF), and IGF1 (10 ng/ml, Peprotech). To 
achieve greater cell purity, motor neurons  were  enriched  
using a gradient centrifugation method  (Corti  et  al.,  2012).  
To monitor the proper acquisition of a motor neuron pheno- 
type, cells were transduced with a lenti-Hb9::GFP construct 
(Marchetto et al., 2008), ﬁxed, and stained for quantiﬁcation 
using established neuronal and motor neuron markers. For 
genetic modiﬁcation, cultures were infected with lentivirus- 
NRXN2 (Origene RC219788, Accession number 
NM_015080), lentivirus-SYNCRIP, lentivirus-SMN, or null 
vector, which was used as a negative control (Simone et al., 
2014). 
 
SH-SY5Y transfection 
The human SH-SY5Y neural cell line was cultured in DMEM 
high glucose medium containing 10% foetal bovine serum 
(FBS), 2.5 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ 
ml streptomycin (all purchased from Euroclone). The  cells  
were transfected with 15 nM SYNCRIP  siRNA  
(Thermoﬁsher, ID s20564) or with select negative control 
(Thermoﬁsher, ID 4390843), which was used as a negative 
control, and harvested after 48 h. 
 
Immunocytochemistry and phenotypic 
analysis of iPSCs and motor neurons 
Cells were ﬁxed in 4% paraformaldehyde for 10 min, permea- 
TM 
bilized with Triton 0.25%, and then blocked with 10% 
0.3% TritonTM X-100 for 1 h at room temperature. We incu- 
bated the cells with primary antibodies to NANOG (1:100, 
Abcam), SSEA-3 (1.100, Covance), ChAT (1:200, Chemicon 
and Millipore), SMI32 (1:500, Covance), hnRNP-Q (1:100, 
Sigma), and NRXN 2a (1:100, Abcam) overnight, and then 
with anti-rabbit, anti-mouse, or anti-goat Alexa Fluor® 488 or 
594 (1:400; Life Technologies) secondary antibody for 1.5 h at 
room temperature. Negative controls were performed for all 
stains. Microphotographs were taken with a LEICA LCS2 con- 
focal microscope. 
 
Motor neuron morphometric analysis 
Phenotypic analysis was performed as described previously 
(Corti et al., 2012; Nizzardo et  al.,  2015;  Allodi  et  al.,  
2016). We quantiﬁed the motor neurons by determining cells 
positive for motor neuron marker and counting 10 randomly 
selected ﬁelds/well. Morphometric and axon length analyses 
were performed by measuring soma diameter and length dis- 
tance between two points (one point from the soma and one   
on the distal axon) (Corti et al., 2012). All quantiﬁcation ana- 
lyses were carried out in a double-blind fashion. For all ima- 
ging, we used a confocal LEICA SP2. 
 
RNA analysis 
Selected cells were treated with proteinase K for 1 h at 50oC 
before  the  addition  of  TRIzol®  LS  (Life  Technologies)   for 
TM 
RNA extraction. DNase treatment using Turbo DNA-free 
(Ambion) was performed to remove contaminating genomic 
DNA. The RNA analysis was processed by DNA vision as 
follows. A sample quality control was performed  on  an  
Agilent 2100 Bioanalyzer  and  quantity  checked  by 
Nanodrop. Next, the TrueSeq mRNA library was constructed, 
followed by Library Quality Control on the Agilent 2100 
Bioanalyzer. Sequencing was performed on  a  HiSeq  2000, 
two samples per lane with a 2 x 100 cycles strategy. 
RNA-Seq reads mapping 
The raw data generated by sequencing were quality-checked 
using the FastQC tool and cleaned of low quality reads, adap- 
tor sequences, and other contaminants. Quality was judged in 
terms of read length distribution, Phred score distribution, and 
nucleotide frequencies obtained from FastQC statistics. STAR 
software (Dobin et al., 2013) was then used to align the reads  
to the reference Homo sapiens Ensembl GRCh37 genome 
(Flicek et al., 2014). Parameters included the removal of non-
canonical junctions, the generation of the XS strand attri- 
bute for all alignments that contain splice junctions, and the 
sorting of the output ﬁles in bam format. The annotation pro- 
vided in Illumina  iGenomes repository was given as  an input  
to the STAR routine, as well as all other routines requiring an 
annotation ﬁle. 
 
Alternative splicing differential 
analysis 
To detect the differential usage of exons between patients and 
controls, data were  processed  using  the  rMATS  tool  (Shen  
et al., 2014). The tool was run in paired-end data processing 
bovine   serum   albumin   in   phosphate-buffered   saline   and mode, with declared length of reads of 101 bp and with a 
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junction anchor length of 4. The statistical model of rMATS 
calculated the inclusion level difference (ILD), P-value, and 
false discovery rate (FDR) for each skipping exon from a    
list obtained from both data and annotation. Exons  were  
then separated on the basis of three conditions: (i) enhanced 
exons (ILD 4 0, |ILD| 4 median|ILD|, FDR 5 0.05); 
(ii) silenced exons (ILD 5 0, |ILD| 4 median|ILD|, FDR 5 0.05); 
and (iii) invariant exons (|ILD| 5 median|ILD|, FDR 4 0.50). 
 
Motif discovery 
The enhanced and silenced cassette exons were analysed to 
identify sequence patterns inside both exons and ﬂanking se- 
quences that discriminate cassette exons differentially included 
in patients. The genomic sequences were retrieved for 
enhanced, silenced, and control exons and their ﬂanking up- 
stream and downstream introns using GeCo++ library (Cereda 
et al., 2011). The ﬂanking intronic regions were selected for 
150 bp ﬁxed length and location 10/ 160 bp upstream and 
+10/+160 bp downstream from the exon. For each sequence,  
the frequency distribution of all possible tetramers was esti- 
mated and collected in a matrix. Projective  non-negative  
matrix factorization  was then applied to identify  a small set   
of distributions (motifs) that approximate the full matrix. The 
factorization rank r corresponds to the number of desired 
motifs. For each sequence, we then calculated  the  
Battacharyya coefﬁcient between the corresponding distribu- 
tion and each motif representing a set of r features. At this  
point, each cassette exon was characterized by a set of 3r 
features comprising upstream intronic, exonic, and down- 
stream intronic sequence features. 
This set of features was then used as variables in logistic 
regressions to identify the parameters of two distinct models  
and distinguish controls from enhanced and  silenced  exons.  
We evaluated the performance of the models by 10-fold cross-
validation AUROC (area under the receiver operating 
characteristic). The entire procedure was repeated for increas- 
ing number of motifs (r) until no AUROC improvement. A 
manuscript with a full description of this method is in 
preparation. 
The obtained motifs were then compared to a set of 119 
vertebrate RBP motifs selected from a publicly available data- 
base (Ray et al., 2013). Again, we used Battacharyya coefﬁ- 
cients to measure the similarity between one of our motifs and 
the tetramer distributions obtained for each of the Ray dataset 
position weight matrices. Signiﬁcant similarities were obtained 
through 200 000 random permutations of the tetramer distri- 
butions. The proportion of permutations, resulting in a higher 
Battacharyya coefﬁcient than the observed one, were used as 
empirical P-value for the comparison. Bonferroni correction 
was applied to take into account the fact that we performed 
119 (Ray dataset) x15 (our motifs) comparisons. 
 
Gene and transcript quantification 
and differential expression 
The ﬁles containing data alignments to genome assembly were 
processed by Cufﬂinks tools (Trapnell et al., 2013) to compute 
the gene and transcript expression levels. Cuffquant  routine  
was run ﬁrst on each individual sample with the ‘-u’ ﬂag, 
supporting correction of multiple reads (i.e. reads mapped at 
multiple loci within the genome). Next, the Cuffnorm routine 
was run to normalize the quantiﬁed expression with respect to 
possible differences in library size, sequencing depth, and/or 
transcript length. The resulting normalized abundances, mea- 
sured as fragments per kilobase of transcript per million 
mapped reads (FPKM), were further used to build a dendro- 
gram plot of all samples and replicates. The results of the 
Cuffquant routine were further employed for the differential 
expression analysis between patients with SMA and controls. 
Thus, the Cuffdiff2 routine was run with the option of mul- 
tiple reads correction. Differentially expressed genes were then 
separated into three sets on the basis of three conditions: (i) 
signiﬁcant upregulation in patients with SMA (log2fold- 
change 4 0, q 5 0.05); (ii) statistically signiﬁcant downregula- 
tion in patients with SMA (log2fold-change 5 0, q 5 0.05); 
and (iii) lack of signiﬁcance between patients and controls. 
 
Functional annotation analysis 
The web-based functional annotation analysis  tool  Database 
for Annotation, Visualization, and Integrated Discovery 
(DAVID) (Huang da et al.,  2009)  was  applied  to  evaluate 
the list of signiﬁcantly differentially used  exons,  and  to  
obtain a set of enriched functional annotations in three do- 
mains: biological process (BP), cellular component (CC), and 
molecular function (MF). For each exon, the corresponding 
gene was considered. The complete set of genes, inclusive of   
all signiﬁcantly up- and downregulated exons, was provided as 
the target (Nt = 4175) and tested against all genes, named 
background (Nb = 29 237). 
The analysis was repeated for the differentially expressed 
genes (P 5 0.05). The complete set of signiﬁcantly up- and 
downregulated genes was provided as the  target  (Nt = 1795) 
and tested against all genes, named background (Nb = 16 122). 
In all analyses, the classiﬁcation stringency was set to high. 
We also used gene set enrichment analysis (GSEA) as a bio- 
informatics tool (Subramanian et al., 2005).  Enrichment  for 
up- or downregulated sets of genes from the REACTOME 
pathway and GO (gene ontology) term database was per- 
formed by running GSEA against the test statistic-ranked list 
of genes in the experiment. Ranking was based on the Cuffdiff 
2-derived test statistic. All REACTOME and  GO term gene 
sets with 415 members in the MSigDB package 
‘c2.all.v3.0.symbols.gmt’ and ‘c5.all.v4.0.symbols.gmt’, re- 
spectively, were downloaded from ftp://gseaftp.broadinstitute. 
org/. 
 
RBP motif enrichment of 
differentially expressed genes 
Among the 29 237 genes analysed, we only kept those  for 
which the most representative  transcript  (i.e.  the  one  with  the 
highest Cuffquant estimated mean FPKM) was fully anno- tated  
as  coding  [i.e.  both  the  30  and  50  untranslated  region 
(UTR) and coding sequence (CDS) were present]. A subset of 
13 853 genes was obtained with the most representative coding 
transcript for each, 1385 from differentially expressed genes. 
Motif enrichment was performed in differentially expressed 
genes as follows. For each transcript and motif, a proﬁle was 
calculated  separately  for  the  50  UTR,  CDS,  and  30  UTR  se- 
quences. Proﬁles were obtained by evaluating the tetramer 
 
 
frequency distribution in 50-bp sliding windows at each pos- 
ition along each sequence and by assigning each position its 
similarity with the motif (Bhattacharyya coefﬁcient). A motif 
was then considered present in a proﬁle if its maximum 
window similarity was 40.7. 
Considering  the  set  of  50  UTR  proﬁles  derived  from  differ- 
entially  expressed  genes  (D50UTR),  we  merged  all  of  the  50 
UTR proﬁles into a unique proﬁle, then starting from  a   
random position we mapped a number of consecutive intervals 
equal  to  the  number  of  D50UTRs  of  matching  length.  We 
counted the number of motifs containing intervals and com- 
pared  it  to  the  number  of  motifs  containing  D50UTRs.  We 
repeated this step 10 000 times and obtained the empirical 
enrichment P-value as  the  proportion  of  iterations  that  gave 
a number of motifs containing intervals equal or greater to the 
number  of  motifs  containing  D50UTR.  The  entire  procedure 
was  repeated  for  CDS  and  30  UTR  proﬁles  derived  from  dif- 
ferentially expressed genes. 
 
Other bioinformatics analysis 
For RNA-Seq data analysis, we used two bioinformatics tools 
that query for enriched GO terms: gene-annotation enrichment 
analysis with DAVID (Huang da et al., 2009) and GSEA 
(Subramanian et al., 2005). Enrichment  for  sets  of  genes  
from the REACTOME pathway and GO term database was 
performed by running GSEA against the test statistic-ranked 
list of genes in the experiment. Ranking was based on the 
Cuffdiff 2-derived test statistic. All REACTOME  and  GO 
term gene sets with 415 members in the MSigDB package 
‘c2.all.v3.0.symbols.gmt’ and ‘c5.all.v4.0.symbols.gmt’, re- 
spectively, were downloaded from ftp://gseaftp.broadinstitute. 
org/. 
 
RNA isolation and quantitative 
real-time PCR 
Total RNA was extracted from cells using the RNeasy® Mini 
Kit (Qiagen) and concentrations measured by a Nanodrop 
spectrophotometer. Only samples  with  ratios  between  1.8  
and 2.0 were analysed further. A total of 1.5 mg of total 
TM 
RNA was reverse-transcribed using the Ready-To-Go kit 
(GE Healthcare). Reverse-transcribed material (5 ng for each 
sample) was ampliﬁed using the TaqMan® Universal PCR 
Master Mix (Applied Biosystems) and appropriate probes to 
evaluate gene expression and exons (probe ID available upon 
request, Supplementary Table 2) in the 7500 Real Time PCR 
System (Software 2.01, Applied Biosystems). Expression levels 
were normalized to the average level of housekeeping gene 18S 
and referred to the relevant control samples. 
 
Western blot analysis 
Western blot analysis was performed as described previously 
(Nizzardo et al., 2014a; Rizzo et al., 2016). Brieﬂy, cells were 
sonicated on ice for 10 min in buffer supplemented with pro- 
tease and phosphatase  inhibitor  cocktail  (Pierce)  (Nizzardo et 
al., 2014a; Rizzo et al., 2016). Alternatively, 20 mg of  frozen 
brain were homogenized in 0.4 ml of protein sample buffer 
containing 2% (w/v) SDS, 10% (v/v) glycerol, 50 mM Tris-HCl 
(pH 6.8), and 0.1 M DTT. A total of 50 mg was 
separated via 10% sodium dodecyl  sulphate–polyacrylamide 
gel electrophoresis (SDS–PAGE).  Proteins were transferred to  
a nitrocellulose membrane and incubated with primary anti- 
bodies overnight at 4oC. The primary antibodies used in these 
experiments were: NFs (1:1000, Sigma), MMP14 
(Thermoﬁsher, 1:1000), SYT13  (1:1300,  Proteintech), 
NRXN1 (1:2000, Abcam), NRXN2a (1:500, Abcam), SMN 
(1:1.000,   BD),   STMN2   (1:2000,   Proteintech), PLP1(1:800, 
Sigma), and hnRNP-Q (1:1000, Sigma). The blots were then 
incubated in secondary antibody: polyclonal anti-rabbit 
(1:2700, Dako) and polyclonal anti-mouse  (1:3200,  Dako).  
The immune complexes were revealed by chemiluminescence 
assay (Amersham). The nitrocellulose membrane was stripped 
and reprobed with anti-actin (1:1000, Sigma) as a loading 
control. Densitometry was performed using ImageJ software. 
 
In vivo experiments in the SMA 
C. elegans model 
Nematodes were grown and handled following standard pro- 
cedures in uncrowded conditions at 20oC on nematode growth 
medium (NGM) agar plates seeded with Escherichia coli strain 
OP50 (Brenner, 1974). The wild-type animals were strain N2, 
variety Bristol. The transgenic strains were: NA1330 gbIs4 
[GBF109 punc-25::smn-1(RNAi); GB301 pchs-2::GFP] III; 
NA1678 gbEx612a  [GB301  pchs-2::GFP];  NA1252 
gbEx540a  [GBF322  punc-119::dsRED;  pelt-2::RFP]; EG1285 
oxIs12   [punc-47::GFP;   lin-15(+)]   X;   NA1355   gbIs4   III, 
oxIs12 III (Gallotta et al., 2016). EG2185 and N2 were pro- 
vided by the Caenorhabditis Genetics Center (CGC) funded by 
NIH Ofﬁce of Research Infrastructure Programs (P40 
OD010440). The following strains were obtained by genetic 
crosses: NA2052 gbIs4 III, gbEx540a, oxIs12 X;  NA2017  
gbIs4 III, gbEx540a. The rescue construct (GBF362 punc- 
119::HRP-2) for pan-neuronal expression of hrp-2 was created 
by PCR fusion (Hobert, 2002) of unc-119 promoter with hrp- 
2, both ampliﬁed from genomic sequences. All primer se- 
quences are available upon request. Germline transformation 
was accomplished as described by Mello et al. (1991) by in- 
jecting  a DNA mixture containing the transgenic construct at    
2 ng/_l (lower concentration, LC) and 20 ng/_l (higher con- 
centration, HC) into the gonad of NA1330 gbIs4 III adult 
animals together with a phenotypic  marker  for  selection  of  
the transgenic progeny. We used pJM371 pelt-2::RFP (RFP 
expression in the nuclei of intestinal cells) as the co-injection 
marker at 30 ng/_l, a kind gift of Prof. J.D. McGhee 
(University of Calgary) (McGhee et al., 2009). Two independ- 
ent transgenic lines were examined for each concentration: 
NA2078  gbIs4  III,  gbEx656a  [GBF362  punc-119::hrp-2 LC; 
pelt-2::RFP]; NA2079 gbIs4 III, gbEx656b [GBF362 punc- 
119::hrp-2 LC; pelt-2::RFP]; NA2075 gbIs4 III, gbEx655a 
[GBF362 punc-119::hrp-2 HC; pelt-2::RFP]; NA2076 gbIs4  
III, gbEx655b [GBF362 punc-119::hrp-2 HC; pelt-2::RFP]. 
Genetic crosses were made to transfer transgenes to the appro- 
priate genetic background to obtain NA2082 gbIs4 III, 
gbEx655a, oxIs12 X: NA2080/2081 gbIs4 III, gbEx656a/b, 
oxIs12 X. In all cases, the presence of the desired transgenes 
was veriﬁed by phenotyping the clonal F2s using a dissecting 
microscope equipped with epiﬂuorescence. Two independent 
clones with the same genotype were examined  after  each  
cross,  and  the  mean  of  the  two  clones  has  been  reported in 
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the results. Animals were immobilized in 0.01% tetramisole 
hydrochloride (Sigma-Aldrich) on 4% agar pads and visualized 
using a Zeiss Axioskop microscope. The phenotypes of dying 
motor neurons were scored by counting the number of ven- 
trally located D-type motor neurons acquiring ﬂuorescence, 
which we previously demonstrated to be speciﬁc for smn-1 
silencing, a late sign of apoptosis, visible  in  the absence  of  
any motor neuron-speciﬁc expression of GFP, different from 
endogenous autoﬂuorescence in the intestine, and never 
observed in control animals (Gallotta et al., 2016). The degen- 
erative phenotype was scored by counting the number of vis- 
ible, and hence viable, D-type motor neurons expressing GFP 
due   to   a   motor   neuron-speciﬁc   promoter   (punc-47::GFP) 
(McIntire et al., 1997). Microscopes used for scoring and ima- 
ging were equipped with epiﬂuorescence and DIC Nomarski 
optics. Epiﬂuorescence and confocal images were collected with  
a  Leica  TCS  SP8  AOBS  microscope,  using  40x  and 
20 objectives, respectively. Epiﬂuorescence images were re- 
constructed using the Tile Scan function of the Leica LAS X 
program, which automatically assembles a picture by taking a 
number of adjoining images of the sample and merges them 
digitally to obtain a larger view. Confocal images were col- 
lected using a 20x objective on a Leica TCS SP8 AOBS con- 
focal microscope. Well-fed, young adult animals were used for 
the backward movement assay (McIntire et al., 1993) to test D-
type motor neuron function. The assay was performed blindly 
on 6-cm diameter NGM plates seeded with bacteria. Using an 
eyelash, the animal was touched ﬁrst on the tail to induce 
forward movement and then on the head to test for backward 
movement. Defective movement was scored when animals were 
unable to fully move backward. For each data-  set, the 
percentage of defective animals among the total  number of 
tested animals was calculated. 
 
In vivo experiments in the SMA 
mouse model 
The SMA�7 mouse transgenic model was used. Heterozygous 
mice (Smn + /-, hSMN2 + / + , SMN�7 + / + , Jackson Laboratories) 
were bred and pups identiﬁed by genotyping (Le et al., 2005). 
All animal experiments were approved by the University of 
Milan and Italian Ministry of Health review boards. 
Homozygous affected pups were cryoanaesthetized and in- 
jected intracerebroventricularly as described previously 
(Nizzardo et al., 2014b) on postnatal Day 1 (P1) with 1011 
particles of adenovirus-associated vector serotype 9 (AAV9) 
vector expressing Syncrip or null vector (SignaGen 
Laboratories). The brain (n = 3/group) was collected and har- 
vested at P7 for western blot analysis. Disease onset, progres- 
sion, survival, and motor function (righting test) were 
monitored after treatment (n = 5/group) as described previ- 
ously (Nizzardo et al., 2014b). All tests were  performed 
blinded to the mouse genotype and treatment. Intercostal mus- 
cles were collected, frozen on dry ice at P10 (n = 3/group), 
cryosectioned (20 mm), and stained for neuromuscular junction 
(NMJ) detection and counting. All sections were saturated 
TM 
with  10%  bovine  serum  albumin  and  0.3%  Triton X-100 
for 1 h at room temperature before incubation with rabbit 
Neuroﬁlament Medium (NF-M, Millipore 1:250) overnight 
at 4oC. The next day, the slides were incubated with Alexa 
Fluor® 488 (1:1000; Life Technologies) and a-bungarotoxin 
555 (1:500, Life Technologies). A minimum of 100  NMJs  
from each muscle were randomly selected and the number of 
denervated/degenerated NMJs was determined for each muscle 
group in each animal based on NF-M/a-BTX staining. 
 
Statistical analysis 
Statistical analyses were carried out in StatsDirect for  
Windows (version 2.6.4) or GraphPad Prism 5 software. Two-
tailed, unpaired Student’s t-test was  used  to  compare two 
groups. Differences in  axonal  length  were  investigated  by the 
Kolmogorov-Smirnov test (http://www.physics.csbsju. 
edu/stats/KS-test.n.plot_form.html). The Kaplan–Meier log 
rank test and logistic regression analysis were used to compare 
lifespans. Contingency and chi-squared tests were used to de- 
termine differences  in the righting test and NMJ innervation.  
All experiments were carried out in at least triplicate. One-way 
ANOVA with Kruskal-Wallis test was used for C. elegans data 
related to statistical analyses. 
The experimental results are provided  as  mean standard 
error of the mean (SEM) or mean standard deviation (SD).   The 
null hypothesis was rejected at the 0.05 level. 
 
Data availability 
The data that support the ﬁndings of this study are openly 
available in GEO at https://www.ncbi.nlm.nih.gov/geo/ refer- 
ence number GSE108094. 
 
 
Results 
Motor neurons generated from SMA 
patient iPSCs present reduced cell 
survival and axonal length in culture 
We previously generated iPSCs from type 1 SMA patients 
and healthy subject ﬁbroblasts using a non-viral, non-inte- 
grating method (Supplementary Table 1; Corti et al., 2012; 
Nizzardo et al., 2014a). Obtained iPSCs exhibited markers 
of pluripotency (Fig. 1A) and were able to differentiate into 
motor neurons using established protocols (Fig. 1B) (Corti  
et al., 2012; Nizzardo et al., 2015). 
Differentiated cells expressed motor neuron-speciﬁc tran- 
scription factors, such as spinal cord progenitor markers 
HB9, ISLET1, and OLIG2 and pan-neuronal markers 
TuJ1, neuroﬁlament, and MAP2. The majority of these 
HB9/ISLET1-positive neurons expressed choline acetyl 
transferase (ChAT) and were positive for motor neuron 
marker SMI-32, demonstrating a mature motor neuron 
phenotype (Fig. 1C). The in vitro differentiation protocol 
yielded a mixed cell population that included non-motor 
neuron cells. Given the limited availability of surface mar- 
kers to isolate and purify motor neurons, we applied a 
physical strategy based on gradient centrifugation. After 
selection, immunocytochemistry revealed that the percent- 
age of ChAT + SMI32 + cells was 89.6 ± 8.4% for cells 
derived from wild-type iPSCs and 87.6 ± 7.7% for cells 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1   SMA iPSCs and the derived motor neurons express typical specific cell type markers. (A) Left: Wild-type and SMA       
iPSCs showed the typical pluripotent stem cell colony morphology under the contrast phase microscope. Right: The cells express the pluripotency 
markers NANOG (red) and SSEA3 (green). Nuclei are labelled with DAPI (blue). Scale bar = 75 mm. (B) Experimental outline for wild-type and 
SMA motor neuron differentiation. (C) Immunocytochemistry of wild-type and SMA motor neurons. The cells were positive for typical motor 
neuron markers SMI32 (green) and ChAT (red) (merge, yellow signal). Nuclei are labelled with DAPI (blue). Scale bar = 75 mm. (D) Eight weeks 
after differentiation, SMA motor neuron survival was significantly reduced compared to wild-type. ***P 5 0.0001, Student t-test. Error bars 
represent SEM. (E) After 8 weeks of culture, SMA motor neurons exhibited significantly reduced axon elongation with respect to wild-type. 
P 5 0.001, Kolmogorov-Smirnov test, five independent experiments. 
 
 
 
derived from SMA-iPSCs. Less than 1% of cells differen- 
tiated from iPSCs expressed the astrocyte marker GFAP 
(data not shown). At  8  weeks,  we  observed  a  reduction 
in the number of motor neurons and axonal length in the 
SMA-iPSC    cultures    compared    to     wild-type-iPSCs  
(P 5 0.0001, Fig. 1D; P 5 0.001, Fig. 1E),  which  is  in 
line with previous reports that SMA iPSC-derived motor 
neurons exhibit reduced survival in long-term  culture 
(Ebert et al., 2009; Nizzardo et al., 2015). 
 
RNA sequencing of SMA motor 
neurons shows specific changes 
in key motor neuron function 
We performed massively parallel deep RNA sequencing tar- 
geting 40M clusters per sample to evaluate global gene 
expression in SMA type  I  and  wild-type  motor  neurons  
to identify differentially expressed/spliced transcripts in 
SMA motor neurons. The analysis revealed a downregula- 
tion of 1084 genes and upregulation of 808 genes out of    
the whole set of  24 691  genes  tested  (fold  change  cut- 
off = 1.5; P 5 0.01; Supplementary Table 3). We identiﬁed 
the 30 transcripts most increased and decreased in abun- 
dance at an FDR of 5% (Fig. 2A). The web-based func- 
tional annotation analysis tool DAVID was applied to 
evaluate the RNA-Seq data and obtain a  set  of  enriched 
GO terms (Supplementary Tables 4 and 5). The most rele- 
vant GO terms are provided in Supplementary Fig. 1. 
Interestingly, in the Reactome analysis we observed a 
signiﬁcant reduction in transcripts  related  to  speciﬁc 
neural assets in SMA motor neurons, including axon- 
related proteins [i.e. stathmin 2 (STMN2), proteolipid 
protein 1 (PLP1)], ion channels, particularly potassium 
channel, and synapses [i.e. synaptotagmin  13  (SYT13),  
and neurexin (NRXN) 1, 2, and 3] (Fig. 2B). An upregu- 
lation  of  neuroﬁlament  heavy  polypeptide  (NEFH)  was 
detected (Table 1). 
Cross-checking our RNA-Seq data (Fig. 2B) with data 
published in the literature, we found sets of genes differen- 
tially expressed between SMA and wild-type motor neurons 
that are likely involved in SMA vulnerability. We validated 
some of the genes by western blot and quantitative PCR 
(qPCR) analysis (Fig. 2C–G). We detected a reduction in 
glutamate ionotropic receptor AMPA-type subunit 1 
(GRIA1)  and,   even   though  not   signiﬁcant,   GRIA2 and 
GRIA4,  which  encode  core  subunits  of  AMPA-type  glu- 
tamate receptors that are critical for glutamatergic excita- 
tory synapses (Zhang et al., 2013). We also found 
dysregulation of IGF-related pathways, detecting the down- 
regulation of insulin-like growth factor 1 (IGF1) and one of 
its substrates, insulin receptor substrate 4 (IRS4), in motor 
neurons, as well as the downregulation of IGF2. Both IGF1 
and IGF2 play a signiﬁcant role in SMA motor neuron 
survival, as we recently demonstrated  (Allodi  et  al.,  
2016). The pathology of SMA has been linked to the endo- 
plasmic  reticulum  (ER)  stress  pathway  and  apoptosis (Ng 
et al., 2015), and we evaluated whether some of these genes 
were deregulated. Some heat shock proteins, unfolded pro- 
tein response (UPR), and apoptosis genes were upregulated, 
suggesting that activation of the UPR pathway in SMA 
motor neurons leads to hyperactivation of the pro-apop-  
totic branches of the UPR pathway. In terms of mRNA 
metabolism, we detected the dysregulation of some proteins 
involved in mRNA splicing and processing, including the 
upregulation of muscle blind-like protein 1 (MBLN1), the 
key gene involved in splicing dysregulation in myotonic 
dystrophy, and the downregulation of heterogeneous nu- 
clear ribonucleoprotein c-like 1 (hNRNPCL1), RNA bind- 
ing  motif  protein  47  (RBM47),  and  epithelial  splicing 
regulatory protein 2 (ESRP2). This alteration can further 
promote transcriptional/splicing alterations. We also con- 
ﬁrmed the downregulation  of some key transcripts altered 
in other SMA models, such as chondrolectin (CHODL1) 
(Gavrilina et al., 2008; Zhang et al., 2008; Baumer et al., 
2009), neuritin (NRN1) (Akten et al., 2011), and cellular 
retinoic acid-binding protein 1 (CRABP1), further support- 
ing the potential role of these genes as downstream targets 
of RNA processing dysfunction induced by  SMN 
deﬁciency. 
 
Differential splicing analysis 
SMN plays a crucial role in the biogenesis of spliceosomal 
snRNPs; thus, its deﬁciency is expected to impact splicing 
(Pellizzoni, 2007; Neuenkirchen et al., 2008). Therefore, we 
started our analysis by searching for cassette exons that 
demonstrate a signiﬁcant difference in the level of inclusion 
between SMA and wild-type motor neurons (alternative 
splicing differential analysis). A total of 12 144 cassette 
exons were deregulated in terms of the inclusion  level;  
2402 and 1035 exhibited a signiﬁcant decrease and in- 
crease in inclusion, respectively, in patient samples with 
respect to the controls  (Supplementary  Table  6). 
Functional annotation analysis of genes containing both 
signiﬁcantly silenced and enhanced cassette exons revealed 
that the most represented GO terms were in the categories 
‘Molecular Function’, ‘Biological Process’, and ‘Cellular 
Component’ (Table 2,  Supplementary  Tables  4  and  7,  
and Supplementary Fig. 2). 
Interestingly, the genes with the greatest degree of differ- 
ential splicing, analysed with Reactome, belonged to func- 
tional classes considered responsible for SMA pathogenesis, 
including axon guidance and synapses (Supplementary 
Table 9). In the vast majority of cases, there was reduced 
inclusion of an exon. 
Among differentially spliced genes, we identiﬁed genes 
involved in motor neuron diseases and function. In particu- 
lar, PIP5K1C is the causative gene of Lethal Congenital 
Contracture Syndrome type 3 (LCCS3), a neurological syn- 
drome in which patients present with rather selective atro- 
phy of the spinal cord anterior horn, similar to  SMA 
patients (Narkis et al.,  2007).  RAC1 has  been implicated  
in motor neuron disease pathogenesis (D’Ambrosi et al., 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Transcriptional analysis of SMA versus wild-type-motor neurons by RNA-Seq analysis shows deregulation of specific 
mRNAs involved in motor neuron functions. (A) Top 60 genes (based on fold change) differentially expressed in SMA versus wild-type 
motor neurons with an FDR of 5%. (B and C) Comparison of RNA-Seq and quantitative RT-PCR data or a selected number of transcripts in wild- 
type and SMA motor neurons. STMN2 (**P 5 0.001), PLP1 (*P 5 0.05), NEFH (*P 5 0.05), NRXN1 (*P 5 0.05), SYN1 (*P 5 0.05), SYN2 
(***P 5 0.0001), EPH2A (*P 5 0.05), SYP (*P 5 0.05), CRABP1 (**P 5 0.01), CDKN1A (***P 5 0.0001), CHODL (*P 5 0.05), GRIA4 (**P 5 0.01). 
Student’s t-test. Error bars represent ± SEM from three independent experiments. (D–G) Representative image of western blot of selected 
proteins in SMA motor neurons compared to wild-type motor neurons: MMP14: **P 5 0.01; SYT13: ***P 5 0.0001; NRXN2: *P 5 0.05; NRXN1: 
***P 5 0.001; NF200: **P 5 0.01; NF160: ***P 5 0.001; NF68: ***P 5 0.001; SMN: ***P 5 0.0001, PLP1: **P 5 0.01; STMN2: ***P 5 0.001, 
Student’s t-test. Data are presented as mean ± SEM from three independent experiments. 
 
 
2014). Furthermore, SINJ1 and RIMS1 were found as al- 
ternative spliced genes speciﬁcally in motor neurons in a 
pathway dependent from FUS protein, a key gene in amyo- 
trophic lateral sclerosis (ALS) (Honda et al., 2013). 
We also identiﬁed genes that were previously detected as 
mispliced in rodent SMA-motor neurons (Zhang et al., 
2013), such as microtubule afﬁnity regulating kinase 2 
(MARK2), calcium/calmodulin dependent protein kinase II 
 
 
 
Table 1 Selected enriched gene sets obtained with 
Reactome analysis that included terms related to axon- 
related proteins, synapses, and potassium channels 
 
Category Gene Expression 
Axon-related protein NEFH Up 
 STMN2 Down 
 PLP1 Down 
 NCAN Down 
 RGMA Down 
 UNC5A Down 
Synapsis NRXN1 Down 
 NRXN2 Down 
 NRXN3 Down 
 SYT7 Up 
 SYT9 Down 
 SYT11 Up 
 SYT13 Down 
 VAMP8 Down 
 SYCP2 Down 
 RIMS4 Down 
 BSN Down 
 SNAP91 Down 
 STXBP1 Up 
Potassium channels KCNA3 Down 
 KCNA5 Down 
 KCNC1 Down 
 KCND2 Down 
 KCNF1 Down 
 KCNG1 Down 
 KCNJ10 Down 
 KCNK3 Down 
 KCNN1 Down 
 KCNN2 Down 
 KCNQ3 Up 
 KCNC4 Up 
 KCNN4 Up 
The selected genes upregulated and downregulated in SMA motor neurons are shown 
in bold and italics, respectively. 
 
 
 
 
delta (CAMK2D), agrin (AGRN) (Zhang et al., 2013), 
which is critical for NMJ maintenance, and M-phase 
phosphoprotein 9 (MPHOSPH9) (Supplementary  Table  
9). Some of these genes with altered splicing were validated 
by RT-PCR in our SMA motor neurons  (Supplementary 
Fig. 7A). 
Overall, our data conﬁrm the role of SMN in splicing 
modulation, particularly for genes related to axon guidance 
and synapses. 
 
RNA binding motif analysis 
We searched for common RNA sequence motifs (i.e. tetra- 
mer distributions) that could predict either silenced or 
enhanced exons in the whole set of  analysed  cassette  
exons. In logistic regression, we found 15 motifs 
(Supplementary Fig. 3) with an area  under  the  curve  
(AUC) of 0.629 and 0.623 for enhanced and silenced 
Table 2 GO terms of differentially spliced genes in 
SMA-motor neurons versus wild-type motor neurons 
(P 5 0.05) using DAVID analysis 
 
 
 
  
 
 
 
 
cassette exons, respectively. Each model assigned three dif- 
ferent weights to each motif in exonic, upstream, and 
downstream intronic regions (Fig. 3A and B). In particular, 
motif 7 (Fig. 3C) in the silenced exonic region had the 
highest positive weight, suggesting an enrichment in these 
regions. We hypothesized that the altered expression of 
transcript variants among multiple genes is  dependent  on 
the interaction of common RBPs with SMN. To examine 
this possibility,  the 15 motifs were compared to a set of  
119 vertebrate RNA binding protein motifs derived from a 
previous work (Ray et al., 2013) using a similarity  meas- 
ure. We completed an inventory of the common motifs and 
their interacting RBPs (Fig. 3B). Signiﬁcant similarities were 
observed, particularly for motif 7, to a group of polyA 
binding proteins involved in splicing and other mRNA pro- 
cessing, transport, and transcription (Glisovic et al., 2008). 
Among these, hnRNPQ (SYNCRIP), HNRNPR, and 
KHDRBS1 have been described as interacting with the full-
length  SMN  protein  (Rossoll  et  al.,  2002;  Pagliarini 
et al., 2015; Geuens et al., 2016). The interaction between 
these polyA binding proteins and SMN are  illustrated  in 
Fig. 3D. SYNCRIP emerged as one of the top RPBs regu- 
lating the splicing of dysregulated transcripts in SMA cells. 
SYNCRIP is an SMN-interacting protein partner highly 
related to hnRNPR (Rossoll et al., 2002). In our experi- 
ments, one of the most frequent motifs with highly prob- 
able interaction with SYNCRIP is the motif identiﬁed as 7 
(Fig. 3C). This ﬁnding indicates a possible link between the 
loss of the interaction between SYNCRIP and full-length 
SMN   and   inefﬁcient   pre-mRNA   splicing   downstream. 
Molecular function RNA binding 
Protein binding 
Cytoskeletal protein binding 
Actin binding 
Tubulin binding 
Microtubule plus-end binding 
Protein serine/threonine kinase activity 
Rab GTPase activator activity 
RNA methyltransferase activity 
Biological process Cell division 
Cell cycle, differentiation, secretion and proliferation 
Regulation of translation and signal transduction 
RNA and snRNA 
Synaptosome 
Flotillin complex 
Cellular component Membranes 
Intracellular organelles 
Mitochondrion and mitochondrial membrane 
Cell junctions 
Microtubules 
Endoplasmic reticulum 
Endocytic vesicle 
GO terms GO category 
  
 
 
 
 
Given the possible role of RBPs in transcription and post- 
transcriptional regulation other than splicing, we wanted to 
test whether enrichment of these motifs can be detected in 
differentially expressed genes. Thus, we devised a motif 
enrichment  procedure  to  test  the  coding,  50,  and  30  UTR 
sequences of differentially expressed genes for motif enrich- 
ment (Supplementary Table 8). We found one motif en- 
riched  in  50  UTRs,  none  in  CDSs,  and  six  in  30  UTRs 
(including  motif  7).  No  motif  was  depleted  in  50  UTRs, 
four  in  CDS,  and  three  in  30  UTRs.  Remarkably,  some 
genes   with   high   motif   7   scores   in   30   UTRs   exhibited 
axonal and synaptic functions, including  NRXN1,  
NRXN2, and SYT13. 
 
NRXN2 protects vulnerable SMA 
patient motor neurons from 
degeneration 
Among the deregulated genes with motif 7, we focused our 
attention on NRXN2 (Fig. 5A), which has already been 
associated with SMA in animal models and is relevant for 
motor neuron survival and function (See et al., 2014). The 
reduction  in  NRXN2  was  further  conﬁrmed  by  qPCR  
(P 5 0.05, Fig. 4B). 
 
To conﬁrm the role of NRXN2 in SMA pathogenesis, we 
investigated whether the upregulation of NRXN2 can halt  
the degeneration of human patient-speciﬁc SMA iPSC- 
derived motor neurons. SMA  motor  neurons  (monitored  
by Hb9::eGFP) were transfected with a  vector  encoding  
the human cDNA for NRXN2, conﬁrming its upregulation 
after infection (P 5 0.01 Fig 4C and D). SMA motor neu- 
rons    present    apparent    cell    autonomous   degeneration 
in vitro after 8 weeks of culturing (Corti et  al.,  2012;  
Allodi et al., 2016), and in the present study overexpression 
of NRXN2 in SMA-motor neurons signiﬁcantly improved 
their survival (P 5 0.0001, Fig. 4E and F) and increased 
neurite length compared to null-treated SMA motor neu- 
rons (P 5 0.001, Fig. 4G). These data suggest that NRXN2 
can rescue the disease phenotype in a human SMA model. 
 
SYNCRIP protects vulnerable SMA 
motor neurons, increasing SMN and 
NRXN2 expression 
We investigated whether the upregulation of SYNCRIP 
could rescue the expression levels of NRXN2, which har- 
bours motif 7, halting the degeneration of human patient- 
speciﬁc SMA iPSC-derived motor neurons (Fig. 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Differentially spliced cassette exons in RNA motif analysis. (A) Heat map of the logistic regression model coefficients for 
silenced (violet) and enhanced (green) exons. Both model coefficients are organized according to the region to which they refer (i.e. intronic 
upstream, exonic and intronic downstream). The 15 motifs are ordered by hierarchical clustering of the corresponding coefficients. (B) Heatmap 
of the comparison between the 15 motifs and a set of known vertebrate RNA binding protein motifs derived from Ray et al. (2013). Motifs are 
ordered as in A, whereas RBPs are ordered by hierarchical cluster. White asterisks correspond to significant similarities (Bonferroni corrected 
empirical P 5 0.01). (C) Motif 7 described probability distribution as a tetramer. Probability accounting for 99% is reported. (D) Known inter- 
actions between proteins significantly similar to motif 7 and SMN1/2 according to the STRING database. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 NRXN2 protects human SMA-motor neurons from degeneration. (A) Significant motif 7 peaks along the NRXN2 transcript 
(RefSeq ID NM_015080). Only significant peaks are reported (Bonferroni corrected P 5 0.01). Red and blue shades represent exon boundaries, 
thinner lines the UTRs. (B) Quantitative PCR analysis showed a significant decrease in the expression of NRXN2 transcript in SMA-motor 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 SYNCRIP protects human SMA motor neurons from degeneration by increasing NRXN2 and SMN levels. 
(A) Representative images of SMA motor neurons after SYNCRIP transfection (Hb9::eGFP, green; SYNCRIP, red). Nuclei are labelled with DAPI 
(blue). (B) q-PCR analysis showed a significant increase in the expression of SYNCRIP, SMN, and NRXN2 transcripts in SMA-motor neurons 
compared to null SMA-motor neurons. ***P 5 0.001, student t-test. Data are presented as mean ± SEM from three independent experiments. 
(C) Western blot representative image of SYNCRIP, SMN, and NRXN2 in SMA motor neurons after SYNCRIP overexpression compared to 
SMA-null cells. Western blot analysis revealed an increased level of SYNCRIP (*P 5 0.05), SMN (*P 5 0.05), and NRXN2 (*P 5 0.05) in SMA 
motor neurons after SYNCRIP overexpression compared to SMA-null cells. Data are presented as mean ± SEM of three independent experi- 
ments. (D) Representative images of SMA motor neurons (Hb9::eGFP, green; ChAT, red) with and without SYNCRIP transfection. Nuclei are 
labelled with DAPI (blue). (E) The number of SYNCRIP SMA-motor neurons in long-term culture was significantly increased compared to SMA 
motor neurons null. SYNCRIP overexpression was protective to motor neurons. ***P 5 0.0001, Student t-test. Data are presented as 
mean ± SEM of five independent experiments. (F) At 8 weeks, SMA motor neurons overexpressing SYNCRIP showed longer axons than SMA 
motor neurons null. P 5 0.001, Kolmogorov-Smirnov test. Scale bar = 75 mm. 
 
 
SMA motor neurons (monitored by Hb9::eGFP) were 
transfected with a vector expressing the human cDNA for 
SYNCRIP (Fig. 5A and B). A subsequent increase in 
NRXN2 was  detected  by  both  qPCR  (P 5 0.0001, 
Fig. 5B) and western blot (P 5 0.05, Fig. 5C), conﬁrming 
our hypothesis of SYNCRIP having a role in its expression. 
SYNCRIP has also been described to modulate the splicing 
of SMN2, promoting the inclusion of exon 7 (Chen et al., 
2008). In line with this ﬁnding, we demonstrated increased 
expression of SMN in SYNCRIP-treated SMA-motor neu- 
rons by q-PCR (P 5 0.001,  Fig.  5B)  and  western blot 
(P 5 0.05, Fig. 5C). Overexpression of SYNCRIP in 
SMA-motor neurons signiﬁcantly improved their survival 
(P 5 0.0001, Fig. 5D and E) and increased neurite length 
compared to null-treated SMA motor neurons (P 5 0.001, 
 
Fig. 5F). Therefore, the missing interaction between SMN 
and SYNCRIP could be the cause of NRXN2 reduction, 
contributing to the SMA phenotype. Our hypothesis is that 
the   complex   SYNCRIP/SMN   can   bind   NRXN2   30UTR 
through motif 7 regulating its mRNA and protein 
expression. 
To validate the hypothesis of a direct interaction between 
SMN, SYNCRIP, and NRXN2, we downregulated 
SYNCRIP with siRNA in the human neural SH-SY5Y cell 
line. SYNCRIP silencing induced a signiﬁcant reduction in 
SMN levels,  as  expected  (mRNA  P 5 0.001,  protein 
P 5 0.05), and a marked decrease in NRXN2 levels in  q- 
PCR and western blot analysis (P 5 0.001, Supplementary 
Fig. 5A–C), conﬁrming the presence of a positive loop 
among    the    three    proteins    (Supplementary    Fig.  5D). 
 
 
than SMA motor neurons null. P 5 0.001, Kolmogorov-Smirnov test. Scale bar = 75 mm. 
are presented as mean ± SEM of five independent experiments. (G) At 8 weeks, SMA-motor neurons overexpressing NRXN2 had longer axons 
independent experiments. (D) Representative images of SMA-motor neurons after NRXN2 transfection (Hb9::eGFP, green; NRXN2, red). Nuclei 
are labelled with DAPI (blue). (E) Representative images of SMA-motor neurons (ChAT, red; Hb9::eGFP, green) with and without NRXN2 
transfection. Nuclei are labelled with DAPI (blue). (F) The number of NRXN2-treated SMA motor neurons in long-term culture was significantly 
increased compared to SMA motor neurons null. NRXN2 overexpression was protective to motor neurons. ***P 5 0.0001, Student t-test. Data 
in SMA motor neurons was confirmed with respect to SMA null (***P 5 0.01, Student’s t-test). Data are presented as mean ± SEM from three 
Representative image of NRXN2 western blot in wild-type motor neurons, SMA motor neurons null and SMA-NRXN2. NRXN2 overexpression 
neurons compared to wild-type. *P 5 0.05, Student’s t-test. Data are presented as mean ± SEM from three independent experiments. (C) 
Figure 4 Continued 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 SYNCRIP ameliorated the disease phenotype in in vivo models of SMA. (A–E) C. elegans; (F–H) mouse model. 
(A) Transgenic animals expressing HRP-2 in all neurons and silenced for smn-1 (right) present fewer dying neurons (arrows) than smn-1(RNAi) 
animals (left). In all panels, anterior is left and ventral is down. The animals were observed using brightfield (top) or epifluorescence (middle and 
bottom). The top and middle panels were reconstructed using the Tile Scan function of the Leica LAS X program. Middle: The co-injection marker 
was expressed in the pharynx and the nuclei of the most posterior intestinal cells (brackets). Bottom: Enlargements of the areas outlined in the 
middle panels around the vulva (#). (B) Quantification of dying motor neurons in non-silenced control (Ctrl), smn-1(RNAi), smn-1(RNAi) 
 
 
 
Intriguingly, we found that even SYT13 and STMN2 ex- 
pression, deregulated in SMA, directly correlate with 
SYNCRIP expression (Supplementary Fig. 4,  P 5 0, 
0001), suggesting that the interaction between SMN and 
SYNCRIP may account for the observed dysregulation of 
other key motor neuron genes in SMA. 
 
Syncrip overexpression ameliorates 
pathological phenotype in SMA in vivo 
models 
We next investigated if overexpression of Syncrip in SMA 
animal models could improve the disease phenotypes. First, 
we used C. elegans depleted of smn-1 in D-type motor 
neurons (Gallotta et  al.,  2016).  The  SYNCRIP  homolog 
in C. elegans is hrp-2 (NM_060648.3), a gene expressed     
in all tissues, including D-type motor neuron (Blazie et al., 
2017), during embryogenesis, larval development, and in 
adult animals (Kinnaird et al., 2004). The protein is loca- 
lized in the nuclei and has nucleic acid binding activity, and 
its depletion causes defects in embryonic and larval devel- 
opment,  fertility  (Kinnaird  et  al.,  2004),  lifespan  (Heintz 
et  al.,  2017),  and  splicing  (Kabat  et  al.,  2009;  Heintz   
et al., 2017). To test whether hrp-2 genetically  interacts 
with smn-1 (Smn1 homologue), we expressed hrp-2 under 
the control of a pan-neuronal promoter (punc-119::hrp-2, 
referred to as HRP-2), in smn-1(RNAi) knocked-down C. 
elegans. The smn-1(RNAi) animals used in this work are 
transgenic for D-type motor neurons with speciﬁc silencing 
of smn-1 at a very high dose (Gallotta et al., 2016). These 
animals  are  viable  and  fertile  but  with  motor  neuron de- 
generation, followed by their death and strong  impairment 
in     backward     locomotion     (Gallotta     et     al.,   2016). 
Overexpression of HRP-2 at two different concentrations 
(low and high) halved the number of dying motor neurons 
per animal, from 8.6 in smn-1(RNAi) to 4.7 in smn-
1(RNAi);HRP-2  LC  and  3.3  in smn-1(RNAi);HRP-2 
HC (P 5 0.0001 in both cases, Fig. 6A and B). The 
rescue obtained is dose-dependent and gene-speciﬁc because 
the expression of an unrelated protein under the same con- 
ditions, such as dsRED ﬂuorescent protein, did not rescue 
this phenotype (nine dying motor neurons/animal). 
Therefore, we used the most effective concentration (high 
concentration) to determine whether HRP-2 was able to 
rescue another earlier phenotype caused by smn-1(RNAi), 
neuronal degeneration. HRP-2 partially rescued the dis- 
appearance of viable motor neurons expressing  GFP;  
51.7%  of  the  19  expected  neurons  degenerated  in  smn- 
1(RNAi);HRP-2 HC compared to 76.5% in smn-1(RNAi) 
animals and 80.7% in smn-1(RNAi);dsRED (P 5 0.0001 in 
both cases, Fig. 6D and E). Finally, we tested the ability of 
HRP-2 to rescue the lack of smn-1 at the functional level. 
Notably, the locomotion defect with smn-1(RNAi) was 
fully rescued by HRP-2 expression, reducing the number 
of animals with an abnormal locomotion behaviour from 
48% in smn-1(RNAi) and 68% in smn-1(RNAi);dsRED to 
14%    in    smn-1(RNAi);HRP-2    HC    (P = 0.0303 and 
P = 0.0001, respectively), which is similar to that observed 
in wild-type animals (9%, P 4 0.05, Fig. 6C). Our results 
demonstrate that HRP-2 plays a conserved role in the SMN 
pathway in neurons, and its overexpression can rescue 
neuron degeneration and death, and the locomotion defects 
caused by smn-1 silencing. 
We also evaluated the effect of Syncrip overexpression in 
a more complex in vivo SMA model, SMAD7, which pre- 
sents a severe SMA phenotype type 1, characterized by loss 
 
 
 
Figure 6 Continued 
expressing dsRED (negative control), and HRP-2 at low (LC) and high (HC) concentrations. ****P 5 0.0001 between smn-1(RNAi);HRP-2 LC and 
HC versus smn-1(RNAi) and smn-1(RNAi); dsRED (one-way ANOVA with Kruskal-Wallis test). Each dot represents the number of apoptotic 
fluorescently-labeled dying motor neurons in a single animal. The median with interquartile range is shown. n is the total number of animals 
observed from two independent transgenic lines. (C) Knock-down of smn-1 in D-type motor neurons leads to a locomotion defect not observed 
in wild-type (WT). This defect is rescued by HRP-2 but not by dsRED expression. *P = 0.0303, smn-1(RNAi);HRP-2 versus smn-1(RNAi) and 
***P = 0.0001 smn-1(RNAi);HRP-2 versus smn-1(RNAi);dsRED (one-way ANOVA with Kruskal-Wallis test). Each dot represents the percentage of 
animals with a defective backward, among 10 animals tested. The median with interquartile range is shown. n is the total number of animals tested 
from at least two independent transgenic lines. (D) Transgenic animals expressing HRP-2 in all neurons and silenced for smn-1 (bottom right) 
present more visible/viable neurons labelled with GFP (arrowheads) than smn-1(RNAi) (top right) or smn-1(RNAi);dsRED animals (bottom left). All 19 
motor neurons are visible in the ventral cord in control animals (top left). Motor neurons are visible because of the expression of GFP in the 
ventral cord, transgene oxIs12[punc-47::GFP]. Additional cells express GFP in the head because of the expression of the pchs-2::GFP co-injection 
marker (brackets, top right and bottom). Red fluorescence is visible in all neurons in dsRED animals (bottom left) or in the intestinal nuclei because 
of pelt-2::RFP co-injection marker (bottom right). (E) Quantification of the percentage of degenerating neurons in wild-type (Ctrl), smn-1(RNAi), and 
smn-1(RNAi) expressing dsRed or hrp-2. The smn-1 knock-down induced the degeneration of motor neurons, and this defect was partially rescued 
by HRP-2 expression. ****P 5 0.0001 smn-1(RNAi);HRP-2 versus smn-1(RNAi) and smn-1(RNAi); dsRED (one-way ANOVA with Kruskal-Wallis 
test). Each dot represents the number of degenerated motor neurons in a single animal, among 19 that are visible in the wild-type. The median 
with interquartile range is shown. n is the total number of animals observed from two independent transgenic lines. (F) The righting reflex was 
significantly improved in SMA� mice injected ICV at P1 with AAV9::Syncrip compared to AAV9::null SMA mice beginning on Day 4. Notably, after 
P6, no AAV9::null SMA mice were able to right, whereas a percentage of SMA mice overexpressing Syncrip maintained the righting reflex function. 
**P 5 0.01, contingency chi-squared test (X2 = 23.76), n = 5 mice/group. (G and H) Quantification of presynaptic NF-M (green) and postsynaptic a-bungarotoxin (red) signal in intercostal muscles showed a significant increase in NMJ innervation in AAV9::Syncrip SMA mice compared to 
AAV9::null SMA mice. *P 5 0.05, contingency chi-squared test (X2 = 5.879), n = 100 NMJs analysed for each animal, three mice/group. 
 
 
 
of motor neurons and neuromuscular function, NMJ de- 
nervation, and dramatically reduced survival (Le et al., 
2005). We intracerebroventricularly injected SMA mice at 
P1 with AAV9, a vector with a particular tropism for the 
CNS (Foust et al., 2009), carrying Syncrip. Syncrip over- 
expression was able to improve righting performance in SMA 
mice (Fig. 6F, P 5 0.01, n = 5, contingency and X2 = 23.76) 
and increase neuromuscular  junction innervation (Fig. 6G,  
P 5 0.05, n = 3, contingency and X2 = 5.879). However, the 
treatment did not show signiﬁcant results in terms of survival 
elongation (data not shown). 
As demonstrated by western blot (Supplementary Fig. 6), 
we  detected  signiﬁcantly  higher  levels  of  SYNCRIP  
(P 5 0.05), as expected, but also SMN and NRXN2  
(both P 5 0.05) in the brains of treated mice, conﬁrming 
in vivo the hypothesis of a positive loop among these three 
genes. 
 
 
Discussion 
SMA is a severe, disabling, inherited neurological disease 
characterized  by  motor  neuron  degeneration  (Pellizzoni 
et al., 1998) and SMN protein depletion. Nusinersen, the 
ﬁrst approved therapeutic compound, became available at  
the end of 2016 (Finkel et al., 2016) (www.curema.org), 
even if it is unclear whether this approach can be resolutive 
for all types of patients. The implementation of successful 
therapy requires better understanding of the molecular 
mechanisms underlying the disease, particularly regarding 
the selectivity of motor neuron loss. Patient-speciﬁc iPSCs 
represent a novel tool for in vitro disease modelling and 
therapeutic discovery in neurodegenerative diseases that in- 
volve a speciﬁc neuronal population (Frattini et al., 2015). 
Here, we differentiated SMA patient iPSCs into motor neu- 
rons, conﬁrming  their reduced survival and axonal length   
in culture. The role of SMN in mRNA processing is well 
established (Pellizzoni et al., 1998), even if the mechanisms 
of this function are still not completely elucidated. 
To understand mRNA-related dysregulation linked to se- 
lective motor neuron vulnerability, we performed whole 
RNA-Seq on SMA and wild-type motor neurons, targeting 
40 M clusters per sample. The gene expression proﬁles 
clearly distinguished the two groups, speciﬁcally 1084 
downregulated and 808 upregulated genes. Among  the  
most deregulated gene sets, we observed a signiﬁcant reduc- 
tion in transcripts linked to speciﬁc neural assets in SMA 
motor  neurons,  including  axon-related  proteins  (STMN2 
and  PLP1),  ion  channels,  particularly  potassium  channel, 
and synapses (i.e. SYT13 and NRXN1, NRXN2, NRXN3). 
We validated the relevant genes by quantitative PCR and/or 
western blot analysis, including genes critical for motor 
neuron function, such as GRIA1, GRIA12, GRIA14 and 
IGF1/IGF12. Remarkably, we conﬁrmed the downregula- 
tion of some key transcripts already found to be altered in 
other SMA models (Pellizzoni et al., 1998), such as 
CHODL1, NRN1, and CRABP1. 
Based on the known role of SMN in the biogenesis of 
spliceosomal snRNPs (Pellizzoni et al., 2002), an effect of 
SMN deﬁciency on splicing is expected. Therefore, we ana- 
lysed the exon alternatively spliced in SMA motor neurons 
compared to wild-type motor neurons. We found 12 144 
deregulated cassette exons belonging to genes involved in 
motor neuron diseases and function, such as MARK2, 
CAMK2D, AGRN, and MPHOSPH9. 
We determined whether differentially spliced  genes  
share some common gene sequence motifs, which could 
predict either silenced or enhanced exons in the whole set   
of cassette exons analysed. We found 15 signiﬁcant motifs 
and compared them to the most complete  set  of  known 
RBP motifs (Ray et al., 2013) to detect signiﬁcant binding 
probabilities. Interestingly, motifs identiﬁed in differen- 
tially spliced exons, particularly motif 7, match those of 
known RBPs involved in mRNA splicing,  transcription,  
and post-transcriptional regulation. As these  processes 
could have an effect in determining the level of gene ex- 
pression, we evaluated the enrichment of these motifs in 
differentially expressed genes. Strikingly, some genes with 
high  motif  7  enrichment  in  the  30  UTR  exhibit  axonal 
and synaptic  functions,  including  NRXN1,  NRXN2,   
and SYT13. 
We focused our attention on NRXN2, which is asso- 
ciated with axonogenesis, synaptogenesis, and synaptic 
function and is relevant for motor neuron survival and 
function. NRXN2, a neuron-speciﬁc gene encoding a 
presynaptic cell adhesion protein that associates with 
postsynaptic proteins, such as neuroligin, is involved  in  
Ca2+ -evoked neurotransmitter release (Ushkaryov et al., 
1992; Missler et al., 2003). Moreover, reduced expression 
and decreased inclusion of exon 12 has been shown in SMN-
deﬁcient zebraﬁsh embryos. Nrxn2a knock-down in 
zebraﬁsh embryos led to motor axon branching defects, as 
well as reduced Ca2+ inﬂux into presynaptic terminals, 
resembling SMA disease (See et al., 2014). Reduced expres- 
sion and altered alternative splicing of Nrxn2a mRNA have 
also been identiﬁed in both the spinal cord and motor 
neurons of mammals, particularly in severe  transgenic 
SMA mice (See et al., 2014). 
Here, we detected for the ﬁrst time reduced expression of 
NRXN2 and decreased inclusion of exon 12 in  human  
SMA motor neurons. Furthermore, our in vitro experi- 
ments showed that NRXN2 upregulation  was  protective  
for SMA motor neurons, improving survival and increasing 
neurite length. Based on these data, we hypothesize that 
NRXN2 alteration can account for the axon and pre-syn- 
aptic defects at neuromuscular endplates in SMA patho- 
physiology, representing a potential non-SMN therapeutic 
target. 
The RBPs with a higher probability of binding motif 7, 
the polyA binding protein, include SYNCRIP (hnRNPQ), 
which was described previously as directly interacting with 
RG-rich domains of full-length SMN protein (Mourelatos   
et al., 2001). Interestingly, SYNCRIP interacts only with 
full-length  SMN,  and  not  with  truncated  or  mutant SMN 
 
 
 
forms identiﬁed in SMA; this may account for the inefﬁ- 
cient pre-mRNA expression and splicing in SMA patients 
(Mourelatos et al., 2001). On the other hand, SYNCRIP 
upregulation has been described in pauci-symptomatic sib- 
lings of SMA patients, supporting its role as a protective 
gene (Pellizzoni et al., 1998). Finally, SYNCRIP is a spli- 
cing modulator of SMN, promoting the inclusion of exon 7 
in SMN2, probably by activating the use of its upstream 30 
splice site (Chen et al., 2008). Intriguingly, SYNCRIP 
emerged as one of the top RPBs with high probability of 
interacting with motif 7, which is also present in NRXN2 
mRNA. We demonstrated that SYNCRIP upregulation res- 
cued NRXN2 levels, suggesting that it can stabilize the 
NRXN2 mRNA and increase its expression by interacting 
with motif 7. Furthermore, increased expression of SMN 
protein was found in SYNCRIP-treated SMA-motor neu- 
rons, conﬁrming the ability of  SYNCRIP  to  enhance  
SMN levels (Chen et al., 2008). We demonstrated that 
SYNCRIP  overexpression  increased  in  vitro  SMA  motor 
neuron survival and axonal outgrowth, likely due to the 
upregulation of SMN and downstream target NRXN2. 
Finally, we demonstrated that SYNCRIP overexpression 
rescued neuron survival and function in vivo in  a  C. 
elegans SMA model and ameliorated the pathological 
phenotype  in  SMN�7  mice.  These  data  highlighted  its 
conserved role in the SMN pathway in neurons, making 
SYNCRIP a promising therapeutic target and modiﬁer in 
SMA. We hypothesized the presence of a positive loop 
among SYNCRIP, SMN, and NRXN2, which was further 
demonstrated in our experiments on SH-SY5Y cells in 
which SYNCRIP was silenced and in the brain of mice 
overexpressed for Syncrip  with  AAV9.  Because  motif  7 
is present in other motor neuron altered genes, such as 
SYT13, we propose that  the  interaction  between  SMN  
and SYNCRIP is crucial in SMA, regulating the  expres- 
sion of several motor neuron genes. Furthermore, this 
hypothesis is supported by the correlation  detected  
between  SYNCRIP  expression and  the  expression  of two 
other key motor neuron genes deregulated in SMA SYT13 
and STMN2. 
Overall, we performed the ﬁrst detailed analysis of the 
correlation between SMN defects, speciﬁc gene expression, 
and splicing alterations in human SMA motor neurons, 
identifying common motif sequences in altered genes. This 
study led us to identify non-SMN therapeutic targets, such  
as NRXN2 and especially SYNCRIP. Moreover, we 
demonstrated that the SMN/SYNCRIP interaction is likely 
responsible for the altered mRNA processing of several key 
motor neuron genes in SMA, contributing to motor neuron 
degeneration, and that its modulation can be crucial to 
modifying the SMA phenotype. The therapeutic approach 
presented in this study can also be combined with the al- 
ready approved SMN-targeted therapy (nusinersen), to 
complement the beneﬁcial effect and in particular when it    
is not completely successful, for example in patients who 
are already symptomatic. 
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